 |
|
ShockDiagnosis and Management
Mark C. Houston, MD;
W. Leigh Thompson, MD, PhD;
David Robertson, MD
Arch Intern Med. 1984;144(7):1433-1439.
Abstract
• Recent investigations have underscored the great diversity in both the causes and manifestations of clinical shock. The emphasis has shifted toward more specific therapy when that has been possible. Pure vasoconstrictors have assumed a secondary therapeutic role, as volume replacement or expansion has become the initial management of shock. Agents, such as naloxone hydrochloride, corticosteroids, fructose diphosphate, amrinone and milrinone, and nonsteroidal anti-Inflammatory agents, while still experimental, offer improved understanding and management of the shock syndrome.
(Arch Intern Med 1984;144:1433-1439)
Author Affiliations
From the Departments of Medicine (Drs Houston and Robertson) and Pharmacology (Dr Robertson), the Cooperative Care Center (Dr Houston), and the Medical Intensive Care Unit (Dr Houston), Vanderbilt University, Nashville, Tenn, and the Department of Medicine, Case Western Reserve University, Cleveland (Dr Thompson). Dr Thompson is a Burroughs Wellcome scholar in clinical pharmacology, and Dr Robertson is a teaching and research scholar of the American College of Physicians.
Footnotes
Accepted for publication Dec 15, 1983.
Reprint requests to Suite S-1125, Department of Medicine, Vanderbilt University, Nashville, TN 37232 (Dr Houston).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Management of cardiogenic shock complicating acute myocardial infarction: towards evidence based medical practice
Williams et al.
Heart 2000;83:621-626.
FULL TEXT
|
